HZB-0071 is under clinical development by Heilongjiang ZBD Pharmaceutical and currently in Phase I for Adenocarcinoma. According to GlobalData, Phase I drugs for Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HZB-0071 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HZB-0071 overview

HZB-0071 is under development for the treatment of adenocarcinoma, gastric cancer and unspecified cancer. It acts by targeting protein kinase B ( AKT).

Heilongjiang ZBD Pharmaceutical overview

Heilongjiang ZBD Pharmaceutical (ZBD Pharmaceutical) develops pharmaceutical products. The company offers various products which include acanthopanax senticosus injection, astragalus injection, shuxuening Injection for cardiovascular treatment; yanhuning injection, norfloxacin and clindamycin hydrochloride capsules for typhoid, respiratory tract infections and anaerobic bacteria; compound paracetamol capsules, Quinlan oral liquid for fever, cough and sore throat; bone peptide injection and hongbao tablets for fracture healing, bone pain and osteoarthritis; pediatric hot quick clear syrup for purging fire and swallowing; lingua plus oral solution and motherwort granules for treatment of irregular menstruation and calcium deficiency. ZBD Pharmaceutical is headquartered in Harbin, Heilongjiang, China.

For a complete picture of HZB-0071’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.